Entrada's Duchenne drug shown to improve muscle function in early trial

Entrada Therapeutics said on Thursday its drug improved a key measure of muscle function in children with Duchenne muscular dystrophy, ​a rare and fatal muscle-wasting disease, in an early-to-mid ‌stage trial.